Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-promoting Effects

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2011 Nov 9

PMID 22065077

Citations 76

Authors

Michaela R Reagan

Irene M Ghobrial

Affiliations

Soon will be listed here.

Abstract

Hematologic malignancies rely heavily on support from host cells through a number of well-documented mechanisms. Host cells, specifically mesenchymal stem cells (MSC), support tumor cell growth, metastasis, survival, bone marrow colonization, and evasion of the immune system. In multiple myeloma, similar to solid tumors, supporting cells have typically been considered healthy host cells. However, recent evidence reveals that many MSCs derived from patients with multiple myeloma (MM-MSC) show significant defects compared with MSCs from nondiseased donors (ND-MSC). These abnormalities range from differences in gene and protein expression to allelic abnormalities and can initiate after less than 1 day of coculture with myeloma cells or persist for months, perhaps years, after removal from myeloma influence. Alterations in MM-MSC function contribute to disease progression and provide new therapeutic targets. However, before the scientific community can capitalize on the distinctions between MM-MSCs and ND-MSCs, a number of confusions must be clarified, as we have done in this review, including the origin(s) of MM-MSCs, identification and characterization of MM-MSCs, and downstream effects and feedback circuits that support cancer progression. Further advances require more genetic analysis of MM-MSCs and disease models that accurately represent MSC-MM cell interactions.

Citing Articles

Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma.

Mera Azain C, Vargas Pasquel J, Quijano Gomez S, Rodriguez-Pardo V Hematol Rep. 2024; 16(4):732-741.

PMID: 39584927 PMC: 11627159. DOI: 10.3390/hematolrep16040070.

Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.

Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T Heliyon. 2024; 10(12):e33091.

PMID: 39021902 PMC: 11252793. DOI: 10.1016/j.heliyon.2024.e33091.

Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma.

Lu Y, Zheng C, Zhang W, Liu X, Zhou Z, Wang Z Cancer Cell Int. 2024; 24(1):116.

PMID: 38539153 PMC: 10976750. DOI: 10.1186/s12935-024-03308-2.

Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.

Bogun L, Koch A, Scherer B, Fenk R, Maus U, Bormann F Blood Adv. 2024; 8(10):2575-2588.

PMID: 38241490 PMC: 11145751. DOI: 10.1182/bloodadvances.2023011632.

Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling.

Wang L, Yi W, Ma L, Lecea E, Hazlehurst L, Adjeroh D Cancers (Basel). 2023; 15(21).

PMID: 37958322 PMC: 10650304. DOI: 10.3390/cancers15215148.

References

Hideshima T, Mitsiades C, Tonon G, Richardson P, Anderson K . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-98. DOI: 10.1038/nrc2189. View

Vincent T, Molina L, Espert L, Mechti N . Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br J Haematol. 2003; 121(2):259-69. DOI: 10.1046/j.1365-2141.2003.04282.x. View

Landowski T, Olashaw N, Agrawal D, Dalton W . Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003; 22(16):2417-21. DOI: 10.1038/sj.onc.1206315. View

Lokhorst H, Lamme T, De Smet M, Klein S, de Weger R, van Oers R . Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994; 84(7):2269-77. View

Dawson M, Chae S, Jain R, Duda D . Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res. 2011; 1(2):144-54. PMC: 3150110. View

Urashima M, Chauhan D, Uchiyama H, Freeman G, Anderson K . CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995; 85(7):1903-12. View

Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X . Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma. 2007; 48(10):2032-41. DOI: 10.1080/10428190701593644. View

Pennisi A, Ling W, Li X, Khan S, Shaughnessy Jr J, Barlogie B . The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009; 114(9):1803-12. PMC: 2738568. DOI: 10.1182/blood-2009-01-201954. View

Hill R, Song Y, Cardiff R, Van Dyke T . Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005; 123(6):1001-11. DOI: 10.1016/j.cell.2005.09.030. View

10.

McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S . Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011; 121(8):3206-19. PMC: 3148732. DOI: 10.1172/JCI45273. View

11.

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

12.

Calabro A, Oken M, Hascall V, Masellis A . Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma.... Blood. 2002; 100(7):2578-85. DOI: 10.1182/blood-2002-01-0030. View

13.

Kirshner J, Thulien K, Martin L, Debes Marun C, Reiman T, Belch A . A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008; 112(7):2935-45. DOI: 10.1182/blood-2008-02-142430. View

14.

Bergfeld S, DeClerck Y . Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010; 29(2):249-61. DOI: 10.1007/s10555-010-9222-7. View

15.

Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P . In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood. 2002; 100(9):3311-8. DOI: 10.1182/blood-2002-01-0102. View

16.

Yaccoby S, Wezeman M, Zangari M, Walker R, Cottler-Fox M, Gaddy D . Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006; 91(2):192-9. PMC: 1592551. View

17.

Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C . Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol. 2009; 38(2):141-53. DOI: 10.1016/j.exphem.2009.11.009. View

18.

Fuhler G, Baanstra M, Chesik D, Somasundaram R, Seckinger A, Hose D . Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res. 2010; 316(11):1816-28. DOI: 10.1016/j.yexcr.2010.03.013. View

19.

Tuhkanen H, Anttila M, Kosma V, Heinonen S, Juhola M, Helisalmi S . Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas. Int J Cancer. 2006; 119(6):1345-53. DOI: 10.1002/ijc.21785. View

20.

McMillin D, Delmore J, Weisberg E, Negri J, Geer D, Klippel S . Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010; 16(4):483-9. PMC: 3786785. DOI: 10.1038/nm.2112. View